CSF3 and acute myeloid leukemia: 10 R/R AML patients received midostaurin, all-trans retinoic acid (ATRA) and CLAG (cladribine, Ara-C, G-CSF) chemotherapy in a phase I trial, achieving a CR rate of 22% and median OS of 3.5 months [34].